Pfizer CEO: We didn't delay vaccine results until after election

FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Pfizer logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/File Photo

(Reuters)


1 photo
Save Story

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (Reuters) — Drugmaker Pfizer "didn't conspire with anyone" to delay releasing efficacy results for the COVID-19 vaccine it developed with German partner BioNTech SE until after the U.S. presidential election, Chief Executive Albert Bourla said at a New York Times conference on Tuesday.

Bourla also said the company has already hit the required safety milestone for the vaccine's phase 3 trial, which is two months of data from around half of the study's roughly 44,000 participants. He said the company is currently preparing that data for submission.

(Reporting by Michael Erman; Editing by Chris Reese)

© Copyright Thomson Reuters 2020

Photos

Most recent Business stories

Related topics

Reuters

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.
    Newsletter Signup

    KSL Weather Forecast

    KSL Weather Forecast
    Play button